Mary Boy
Overview
Explore the profile of Mary Boy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Charles-Schoeman C, Wicker P, Gonzalez-Gay M, Boy M, Zuckerman A, Soma K, et al.
Semin Arthritis Rheum
. 2016 Jul;
46(3):261-271.
PMID: 27443588
Objectives: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The implications of treatment with tofacitinib on cardiovascular (CV) risk in RA are unknown. Therefore,...
2.
Krishnaswami S, Boy M, Chow V, Chan G
Clin Pharmacol Drug Dev
. 2016 Apr;
4(2):83-8.
PMID: 27128212
Tofacitinib is an oral Janus kinase inhibitor. This randomized, double-blind, parallel-group, placebo-controlled study was the first evaluation of tofacitinib in humans. The objectives were to characterize the safety and tolerability,...
3.
Charles-Schoeman C, Gonzalez-Gay M, Kaplan I, Boy M, Geier J, Luo Z, et al.
Semin Arthritis Rheum
. 2016 Apr;
46(1):71-80.
PMID: 27079757
Cardiovascular (CV) morbidity and mortality are increased in patients with active, untreated rheumatoid arthritis (RA), despite lower levels of total and low-density lipoprotein cholesterol reported in individuals with active RA...
4.
Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, et al.
Arthritis Res Ther
. 2015 Dec;
17:362.
PMID: 26669566
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib modulates the signaling of cytokines that are integral to lymphocyte activation, proliferation, and function....
5.
Krishnaswami S, Chow V, Boy M, Wang C, Chan G
J Clin Pharmacol
. 2013 Sep;
54(1):46-52.
PMID: 24030917
The pharmacokinetics (PK) of tofacitinib were assessed in patients with mild (Cockcroft-Gault creatinine clearance >50 and ≤80 mL/min), moderate (≥30 and ≤50 mL/min), and severe (<30 mL/min) renal impairment, and...